InterPAD - DETAILS

tanshinone, tanshinone I, tanshinone II A, tanshinone II B, tanshinone IIA, tanshinone IIB, TTE-50

No.	Title	Href
1	Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer. Phytother Res. 2019 Jun;33(6):1658-1669. doi: 10.1002/ptr.6353.	`Click`
2	Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway. Phytother Res. 2019 Sep;33(9):2298-2309. doi: 10.1002/ptr.6392.	`Click`
3	Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting β-catenin nuclear translocation. J Biochem Mol Toxicol. 2021 Jan;35(1):e22620. doi: 10.1002/jbt.22620. Epub 2020 Sep 4. Erratum in: J Biochem Mol Toxicol. 2021 Apr;35(4):e22790.	`Click`
4	Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway. Oncol Rep. 2020 Feb;43(2):503-515. doi: 10.3892/or.2019.7453.	`Click`
5	Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation). Brain Res. 2021 Sep 1;1766:147515. doi: 10.1016/j.brainres.2021.147515.	`Click`
6	Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance. Cell Death Dis. 2021 Feb 4;12(2):152. doi: 10.1038/s41419-021-03434-z.	`Click`
7	The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway. Int J Biochem Cell Biol. 2019 Jan;106:8-20. doi: 10.1016/j.biocel.2018.10.008.	`Click`
8	Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells. Onco Targets Ther. 2018 Mar 29;11:1777-1785. doi: 10.2147/OTT.S161534.	`Click`
9	Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1. Phytomedicine. 2024 Jan;123:155191. doi: 10.1016/j.phymed.2023.155191.	`Click`

No.

Title

Href

Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer. Phytother Res. 2019 Jun;33(6):1658-1669. doi: 10.1002/ptr.6353.

Click

Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway. Phytother Res. 2019 Sep;33(9):2298-2309. doi: 10.1002/ptr.6392.

Click

Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting β-catenin nuclear translocation. J Biochem Mol Toxicol. 2021 Jan;35(1):e22620. doi: 10.1002/jbt.22620. Epub 2020 Sep 4. Erratum in: J Biochem Mol Toxicol. 2021 Apr;35(4):e22790.

Click

Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway. Oncol Rep. 2020 Feb;43(2):503-515. doi: 10.3892/or.2019.7453.

Click

Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation). Brain Res. 2021 Sep 1;1766:147515. doi: 10.1016/j.brainres.2021.147515.

Click

Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance. Cell Death Dis. 2021 Feb 4;12(2):152. doi: 10.1038/s41419-021-03434-z.

Click

The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway. Int J Biochem Cell Biol. 2019 Jan;106:8-20. doi: 10.1016/j.biocel.2018.10.008.

Click

Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells. Onco Targets Ther. 2018 Mar 29;11:1777-1785. doi: 10.2147/OTT.S161534.

Click

Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1. Phytomedicine. 2024 Jan;123:155191. doi: 10.1016/j.phymed.2023.155191.

Click

Name	Tanshinone IIA
PubChem CID	164676
Molecular Weight	294.3g/mol
Synonyms	tanshinone, tanshinone I, tanshinone II A, tanshinone II B, tanshinone IIA, tanshinone IIB, TTE-50
Formula	C₁₉H₁₈O₃
SMILES	CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C
InChI	1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3
InChIKey	HYXITZLLTYIPOF-UHFFFAOYSA-N
CAS Number	568-72-9
ChEMBL ID	CHEMBL187266
ChEBI ID	CHEBI:108595
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Chineses Pinyin	DanShen
Use Part	Root
Habitat	GanSu, SiChuan, GuiZhou
Flavor	Bitter
Meridian Tropism	Heart; Liver
Species	>Kingdom: Viridiplantae 　-->Phylum: Streptophyta 　　-->Class: Equisetopsida 　　　-->Order: Lamiales 　　　　-->Family: Lamiaceae 　　　　　-->Genus: Salvia 　　　　　　-->Species: Salvia miltiorrhiza

Pair Name	Tanshinone IIA, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	CASP3	hsa836
	Down-regulation	Phosphorylation	PIK3CA	hsa5290
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
In Vivo Model	Equal numbers of A549 cells (2×10⁶ cells) were resuspended in 100 ml of normal saline and subcutaneously injected into unilateral axillary fossae of 4-week-old nude mice (BALB/c-nu).
Result	The combination of Tan IIA and cisplatin exhibited the most significant difference. Tanshinone IIA may function as a novel option for combination therapy for non-small-cell lung cancer treatment.

Pair Name	Tanshinone IIA, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Down-regulation	Expression	CTNNB1	hsa1499
In Vitro Model	MCF-7(DOX/R)	Invasive breast carcinoma	Homo sapiens (Human)	CVCL_C4M9
Result	Tan II A could be used as a potential chemosensitizer in combination with Dox for breast cancer chemotherapy.

Pair Name	Tanshinone IIA, Imatinib
Partner Name	Imatinib
Disease Info	[ICD-11: 2A20.1]	Chronic myelogenous leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	MKI67	hsa4288
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Down-regulation	Phosphorylation	PIK3CA	hsa5290
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	Jurkat	Childhood T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0065
In Vivo Model	TBI-152 cells (4×10⁶) were injected into the right flank of the mice.
Result	The results revealed that Tan IIA enhanced the inhibitory effect of imatinib on TIB‑152 cell proliferation, migration and invasion, and induced apoptosis, which may be associated with inhibition of the PI3K/AKT/mTOR signaling pathway.

Pair Name	Tanshinone IIA, TNF-related apoptosis inducing ligand
Partner Name	TNF-related apoptosis inducing ligand
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	STAT3	hsa6774
	Up-regulation	Expression	TNFRSF10A	hsa8797
	Up-regulation	Expression	TNFRSF10B	hsa8795
In Vitro Model	U-87MG ATCC	Glioblastoma	Homo sapiens (Human)	CVCL_0022
In Vitro Model	U-251MG	Astrocytoma	Homo sapiens (Human)	CVCL_0021
In Vivo Model	Each mouse was injected subcutaneously with 0.2 mL of U87 cells (1×10⁵ cells/ml) at the hind limb.
Result	T-IIA increases TRAIL-induced apoptosis by downregulating STAT3 and upregulating DR4 and DR5, indicating T-IIA therapy as a novel treatment strategy for TRAIL-resistant GBM.

Pair Name	Tanshinone IIA, Aurora kinase inhibitor
Partner Name	Aurora kinase inhibitor
Disease Info	[ICD-11: 2B66.0]	Oral squamous cell carcinoma		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Phosphorylation	AURKB	hsa9212
Gene Regulation	Down-regulation	Phosphorylation	H3C1	hsa8350
In Vitro Model	SCC-9	Tongue squamous cell carcinoma	Homo sapiens (Human)	CVCL_1685
	SCC-15	Tongue squamous cell carcinoma	Homo sapiens (Human)	CVCL_1681
	SCC-25	Tongue squamous cell carcinoma	Homo sapiens (Human)	CVCL_1682
	CAL-27	Tongue adenosquamous carcinoma	Homo sapiens (Human)	CVCL_1107
In Vivo Model	The OSCC xenograft models were constructed by s.c. injection of CAL27 (2×10⁶) or SCC25 (3×10⁶) cells into the right flank of 6-week-old athymic nude mice (n = 5).
Result	Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance

Pair Name	Tanshinone IIA, Nutlin-3
Partner Name	Nutlin-3
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Autophagy
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
Gene Regulation	Down-regulation	Expression	MTOR	hsa2475
In Vitro Model	SUP-B15	Childhood B acute lymphoblastic leukemia with t	Homo sapiens (Human)	CVCL_0103
	NALM-6	Adult B acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0092
	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens (Human)	CVCL_0064
Result	The results of this study demonstrate that the Nutlin-3 plus Tanshinone IIA combination exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways, although further investigation is warranted. Small-molecule MDM2 antagonists plus Tanshinone IIA may thus be a promising strategy for the treatment of acute leukemia.

Pair Name	Tanshinone IIA, Sorafenib
Partner Name	Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Epithelial-mesenchymal transition
Gene Regulation	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	Huh-7	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0336
	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	A combination therapy using Tan-IIA and sorafenib or SC-1 could be a promising approach to target HCC, and further preclinical investigations are warranted to establish their synergetic advantage.

Pair Name	Tanshinone IIA, Anti-mouse PD-1
Partner Name	Anti-mouse PD-1
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Immunomodulatory
Gene Regulation	Down-regulation	Expression	ADGRL4	hsa64123
	Up-regulation	Expression	CLDN5	hsa7122
	Down-regulation	Expression	JAK1	hsa3716
	Down-regulation	Expression	JAK2	hsa3717
	Up-regulation	Expression	OCLN	hsa100506658
	Up-regulation	Expression	TJP1	hsa7082
In Vitro Model	Jurkat	Childhood T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0065
	bEnd.3	Healthy	Mus musculus (Mouse)	CVCL_0170
	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
	CTLL-2	Healthy	Mus musculus (Mouse)	CVCL_0227
Result	This study reveals a new mechanism between TSA and ELTD1 for vascular normalization, suggesting that therapeutic or pharmacological intervention with ELTD1 may enhance the efficacy of PD-1 inhibitors in HCC.